文献速递头颈外科

延长药物预防与高危头颈癌患者静脉血栓栓塞风险的关联

Association of Prolonged-Duration Chemoprophylaxis With Venous Thromboembolism in High-risk Patients With Head and Neck Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2021-01-01

该回顾性队列研究纳入247例Caprini评分≥8且接受肿瘤手术的头颈癌患者,比较传统预防与延长药物预防(术后≥7天)对30天内静脉血栓栓塞(VTE)和出血事件的影响。多因素分析显示延长预防与VTE风险降低独立相关(OR 0.04,95%CI 0.001-0.46),但出血事件数值上增加(4.3% vs 0.9%),需权衡利弊。

要点

  • 延长药物预防(≥7天)与高危头颈癌患者VTE风险降低独立相关(OR 0.04)。
  • 延长预防组出血事件发生率为4.3%,传统组为0.9%,需警惕非致命性出血。
  • 该人群最佳药物预防时长尚需进一步研究确定。

核心结论

  • 延长药物预防可能降低高危头颈癌患者VTE风险,但出血事件增加需谨慎权衡。

研究设计与样本

  • 回顾性队列研究,纳入2014年1月1日至2020年2月1日期间在三级转诊中心接受住院肿瘤手术的活检确诊头颈癌且Caprini评分≥8的患者,最终247例纳入分析。

主要发现

  • 传统预防组VTE发生率为4.7%(5/106),延长预防组为0.7%(1/141),OR 0.15(95%CI 0.003-1.33)。
  • 多因素logistic回归显示延长药物预防与VTE风险降低独立相关(OR 0.04,95%CI 0.001-0.46)。
  • 出血事件发生率传统组为0.9%(1/106),延长预防组为4.3%(6/141),OR 4.64(95%CI 0.55-217.00)。

关键数值与推荐

  • 延长药物预防定义为术后药物预防≥7天。
  • 高-risk定义为Caprini风险评分≥8。
  • 主要结局为术后30天内VTE和出血事件。

临床怎么用

  • 对Caprini评分≥8的头颈癌手术患者,可考虑延长药物预防以降低VTE风险。
  • 延长预防需个体化评估出血风险,密切监测出血并发症。

局限性

  • 回顾性研究设计,样本量较小(247例),事件数少,置信区间宽。
  • 单中心三级转诊中心数据,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Venous thromboembolism (VTE) is associated with substantial morbidity and is the most common factor associated with preventable death among hospitalized patients. Data from otolaryngologic studies suggest that the risk of VTE may be underestimated among high-risk patients, particularly among those undergoing oncologic procedures. The incorporation of prolonged-duration chemoprophylaxis (PDC) into preventive therapy has been associated with substantial decreases in VTE incidence among patients undergoing oncologic surgery. However, bleeding remains a major concern among otolaryngologists, and substantial variation exists in the use of thromboprophylaxis. OBJECTIVE: To assess the association between PDC and VTE in high-risk patients with head and neck cancer undergoing oncologic procedures. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study identified 750 patients with biopsy-confirmed head and neck cancer and a Caprini risk score of 8 or higher who underwent inpatient oncologic surgery at a tertiary care referral center between January 1, 2014, and February 1, 2020. After exclusions, 247 patients were included in the study; patients were divided into 2 cohorts, traditional and PDC, based on the duration of prophylaxis. Univariate and multivariate analyses were performed to examine the development of VTE and bleeding-associated complications during the 30-day postoperative period. Data were analyzed from April 1 to April 30, 2020. EXPOSURES: PDC, defined as 7 or more postoperative days of chemoprophylaxis. MAIN OUTCOMES AND MEASURES: VTE and bleeding events during the 30-day postoperative period. RESULTS: Among 247 patients (mean [SD] age, 63.1 [11.1] years; 180 men [72.9%]) included in the study, 106 patients (42.9%) received traditional prophylaxis, and 141 patients (57.1%) received PDC. The incidence of VTE was 5 of 106 patients (4.7%) in the traditional cohort and 1 of 141 patients (0.7%) in the PDC cohort (odds ratio [OR], 0.15; 95% CI, 0.003-1.33). In the multivariate logistic regression analysis, PDC was independently associated with reductions in the risk of VTE (OR, 0.04; 95% CI, 0.001-0.46). The incidence of bleeding events was 1 of 106 patients (0.9%) in the traditional cohort and 6 of 141 patients (4.3%) in the PDC cohort (OR, 4.64; 95% CI, 0.55-217.00). CONCLUSIONS AND RELEVANCE: The use of chemoprophylaxis for high-risk patients with head and neck cancer remains a high-priority topic. The results of this study suggest that PDC may be associated with reductions in VTE among this patient population. However, the associated increase in nonfatal bleeding events warrants careful consideration and further highlights the need to determine an optimal duration for chemoprophylaxis among this distinct cohort.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Tipirneni KE, Bauter L, Arnold MA, et al. Association of Prolonged-Duration Chemoprophylaxis With Venous Thromboembolism in High-risk Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33443564. doi:10.1001/jamaoto.2020.5151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。